Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Intel Shareholders Are Suing Company After 29% Stock Decline

Intel is being sued by its shareholders. The people claim that the blue chipmaker concealed the impact that the decline in PC sales had caused; its stock price dipped close to 29% in a single day. The lawsuit, filed in the US state of California, claims that Intel was too slow in disclosing information about […] The post Intel Shareholders Are Suing Company After 29% Stock Decline appeared first…

Intel Shareholders Are Suing Company After 29% Stock Decline

Intel is facing legal action from its shareholders after experiencing a significant 29% drop in its stock price within a single day. The lawsuit, filed in California, alleges that the company concealed the impact of the declining personal computer (PC) sales and an inventory glut on its revenue. The stock value decline resulted in a loss of approximately US$140 billion.

The issue extends beyond just sales performance; Intel has struggled with its 14nm fabrication process, which was held onto for an extended period, only being replaced with its 10nm Intel 7 process in 2021. The company also faced major engineering flaws in its top-tier 13th and 14th Gen Core i9 processors, rendering them unusable due to voltage spikes.

On the bright side, Intel's Arrow Lake and Core Ultra 200S Plus processors have been well-received. However, the company's inventory glut can be partly attributed to the limited supply of GPUs from NVIDIA, which has caused issues for gamers who are in high demand for RTX 50 Series GPUs. Additionally, the rise in the cost of memory and storage has further complicated Intel's ability to capitalize on the growing demand for datacenter chips.

Written by urgent.news from Lowyat.NET's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at lowyat.net →

More in Finance & Markets

GSK: 3 Key Takeaways for Long-Term Investors

Cost discipline is offsetting R&D investment without squeezing margins, the financial foundation for sustained portfolio transformation.

  • GSK reaffirmed full-year 2026 guidance, with sales growing 5% to £8.9 billion
  • Accelerated R&D pipeline initiated 18 phase 3 clinical trials in 2026, aiming for 22 by year-end

More from Tuesday 17 November →